Interferon Gamma-1B
Osteopetrosis
FDA Office of Orphan Products Developmentprotein_peptidePhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Osteopetrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
Alemtuzumab Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
BUSULFANUM Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
Rabbit Anti-Thymocyte Globulin Columbia University | Phase 2/3 | B |
Cyclophosphamide Columbia University | Phase 2/3 | B |
View all 9 →
Same molecule, other indications
Interferon Gamma-1B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →